Science and Technology Science and Technology
Fri, August 14, 2009
Thu, August 13, 2009

BioElectronics Corporation: BioElectronics Launches Direct Response Television Initiative


Published on 2009-08-13 07:24:28, Last Modified on 2009-08-13 07:24:36 - Market Wire
  Print publication without navigation


FREDERICK, MD--(Marketwire - August 13, 2009) - BioElectronics Corp. (PINKSHEETS: [ BIEL ]), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it is launching a direct response television (DRTV) initiative to market its ActiPatch® Therapy and Allay™ brands to the mass market. BioElectronics has retained industry leader, Schulberg MediaWorks as its marketing partner. Work on the DRTV spots has already begun with initial airing expected within 60 days. Initially, the Canadian and selected other English speaking markets will be targeted, but the U.S. market will also be heavily targeted once FDA clearance is received.

"We have selected SMW (Schulberg MediaWorks) as our partner based on its impressive record of both success and integrity. SMW, which is one of the pioneers in infomercial advertising, has an impressive track record with more than $700 million in DRTV sales and more than one billion viewers of its innovative programs," commented Andrew Whelan, CEO of BioElectronics. "In addition to impressive creative and video production capabilities, they also bring to the table extensive operational expertise in media buying, web design, order processing, and fulfillment. Our management team and board of directors are pleased that a DRTV firm of SMW's quality has agreed to be our partner. We are expecting this initiative to be a major revenue generator for the Company."

"We believe ActiPatch Therapy and Allay are strong brands for DRTV marketing," commented Jon Schulberg, President of Schulberg MediaWorks. "The issue of the potential dangers of Tylenol® and acetaminophen is already resonating with the public and we believe many consumers are looking for drug-free alternatives. We will be working closely with the BioElectronics team to help communicate the message to the public that the ActiPatch Therapy and Allay products are effective alternatives to taking potentially dangerous medications. We look forward to making this initiative a success for BioElectronics and its shareholders."

About BioElectronics Corporation

BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx™ Devices, HealFast™ Therapy ([ www.healfasttherapy.com ]) and the Allay™ family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see [ http://www.BioElectronicsCorp.com ].

About Schulberg MediaWorks

Schulberg MediaWorks is considered a pioneer in the field of infomercial advertising. The team has directed, written and produced some of the most successful direct response television (DRTV) campaigns of all time and has been honored with virtually every infomercial industry award, including twice winning Infomercial of the Year (Personal Power with Tony Robbins and Making Love Work with Barbara DeAngelis) in addition to being awarded Best Writer, Best Producer and Best Director. SMW clients include Tempur-Pedic, Select Comfort, PureSleep, HBO, Sega, Time-Life, Guthy-Renker, Fitness Quest, Reliant, QVC, Sharper Image, Rossetta Stone, Rhino Records, Delonghi, and Sony Music. More information on Schulberg MediaWorks can be seen at [ www.smw.tv ].

Tylenol is a registered trademark of McNeil pharmaceutical, Inc.

Contributing Sources